Protalix Biotherapeutics Inc Stock TEL AVIV STOCK EXCHANGE
Equities
US74365A1016
Biotechnology & Medical Research
Sales 2024 * | 74.06M 27.37B 101M | Sales 2025 * | 127M 47.06B 174M | Capitalization | 83.58M 30.88B 114M |
---|---|---|---|---|---|
Net income 2024 * | 17M 6.28B 23.2M | Net income 2025 * | 70M 25.86B 95.53M | EV / Sales 2024 * | 1.13 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.66 x |
P/E ratio 2024 * |
5.43
x | P/E ratio 2025 * |
1.41
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.27% |
Latest transcript on Protalix Biotherapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 19-06-29 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 19-07-21 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 20-07-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 19-11-30 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 19-11-30 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 14-10-31 |
1st Jan change | Capi. | |
---|---|---|
+29.85% | 48.16B | |
-0.60% | 41.73B | |
+44.59% | 41.03B | |
-5.31% | 28.77B | |
+10.87% | 25.59B | |
-22.52% | 18.96B | |
+8.74% | 12.92B | |
+28.64% | 12.03B | |
-2.40% | 11.77B |